Crossref
journal-article
Elsevier BV
Annales d'Urologie (78)
References
100
Referenced
12
10.1016/S0022-5347(05)65765-5
/ J Urol / Local anesthesia for ultrasound guided prostate biopsy: a prospective randomized trial comparing 2 methods by Alavi (2001)10.1046/j.1464-410x.2000.00576.x
/ BJU Int / Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study by Aron (2000)10.1016/S0090-4295(01)01264-X
/ Urology / Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria by Bartsch (2001)10.1002/(SICI)1097-0045(19990701)40:2<130::AID-PROS9>3.0.CO;2-X
/ Prostate / Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction by Boer (1999)10.1016/S0094-0143(02)00189-1
/ Urol Clin North Am / Contemporary pathology of prostate cancer by Bostwick (2003)10.1016/S0022-5347(17)35485-X
/ J Urol / The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma by Brawer (1993)10.1016/S0022-5347(05)67646-X
/ J Urol / Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer by Brawer (2000)10.1016/S0022-5347(17)37401-3
/ J Urol / Screening for prostatic carcinoma with prostate specific antigen by Brawer (1992)10.1016/S0094-0143(02)00183-0
/ Urol Clin North Am / Biochemical staging of prostate cancer by Canto (2003)10.1016/S0022-5347(05)66082-X
/ J Urol / Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications? by Carey (2001)10.1016/S0022-5347(17)38971-1
/ J Urol / Evaluation of transrectal ultrasound in the early detection of prostate cancer by Carter (1989){'key': '10.1016/j.anuro.2004.06.003_BIB12', 'first-page': '3055', 'article-title': 'Diagnosis and staging of prostate cancer', 'author': 'Carter', 'year': '2002'}
/ Diagnosis and staging of prostate cancer by Carter (2002)10.1001/jama.1992.03480160073037
/ JAMA / Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease by Carter (1992)10.1016/S0022-5347(01)61785-3
/ J Urol / Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less by Carvalhal (1999)10.1016/S0022-5347(17)32300-5
/ J Urol / Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves by Catalona (1994)10.1001/jama.279.19.1542
/ JAMA / Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial by Catalona (1998)10.1016/S0090-4295(99)00602-0
/ Urology / Lowering PSA cutoffs to enhance detection of curable prostate cancer by Catalona (2000)10.1016/S0022-5347(17)35233-3
/ J Urol / Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men by Catalona (1994)10.1001/jama.1997.03540420048028
/ JAMA / Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements by Catalona (1997)10.1001/jama.1993.03510080052031
/ JAMA / Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening by Catalona (1993)10.1001/jama.1995.03530150038031
/ JAMA / Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening by Catalona (1995)10.1016/S0090-4295(00)00637-3
/ Urology / Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging by Catalona (2000)10.1016/S0090-4295(99)80487-7
/ Urology / Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer by Chen (1996)10.1016/S0022-5347(17)38325-8
/ J Urol / Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters by Chybowski (1991)10.1016/S0022-5347(17)40211-4
/ J Urol / Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen by Cooner (1990)10.1002/pros.10092
/ Prostate / Worry and attitude of men in at-risk families for prostate cancer about genetic susceptibility and genetic testing by Cormier (2002)10.1016/S0022-5347(01)67458-5
/ J Urol / The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis by Cupp (1995){'key': '10.1016/j.anuro.2004.06.003_BIB28', 'first-page': '25', 'article-title': "Interprétation clinique d'une élévation du taux des PSA sanguins", 'volume': '8', 'author': 'Cussenot', 'year': '2002', 'journal-title': 'Méd Thér'}
/ Méd Thér / Interprétation clinique d'une élévation du taux des PSA sanguins by Cussenot (2002)10.1016/S0953-6205(00)00134-5
/ Eur J Intern Med / Noninvasive detection of genetic instability in cells from prostatic secretion as a marker of prostate cancer by Cussenot (2001)10.1016/S0360-3016(02)02797-9
/ Int J Radiat Oncol Biol Phys / Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer by D'Amico (2002)10.1200/JCO.2000.18.6.1164
/ J Clin Oncol / Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer by D'Amico (2000)10.1016/S0022-5347(17)36424-8
/ J Urol / The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection by Danella (1993)10.1002/ijc.1588
/ Int J Cancer / Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial by de Koning (2002)10.1016/S0090-4295(99)00153-3
/ Urology / PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL by Djavan (1999)10.1016/S0090-4295(99)00329-5
/ Urology / Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? by Djavan (1999)10.1016/S0022-5347(17)32460-6
/ J Urol / Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography by Ellis (1994)10.1046/j.1464-410X.1997.00144.x
/ Br J Urol / Morbidity of ultrasound-guided transrectal core biopsy of the prostate without prophylactic antibiotic therapy by Enlund (1997)10.1016/S0022-5347(17)32370-4
/ J Urol / Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C) by Epstein (1994)10.1016/S0022-5347(01)65322-9
/ J Urol / Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate by Eskew (1997)10.1016/S0090-4295(01)01304-8
/ Urology / Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging by Fang (2001)10.1016/S0094-0143(05)70154-3
/ Urol Clin North Am / Indicators of pathologic stage of prostate cancer and their use in clinical practice by Feneley (2001)10.1001/jama.1995.03520280035036
/ JAMA / A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer by Gann (1995)10.1016/S1078-1439(02)00177-1
/ Urol Oncol / A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men by Graefen (2002){'key': '10.1016/j.anuro.2004.06.003_BIB44', 'first-page': '627', 'article-title': 'Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia', 'volume': '20', 'author': 'Guess', 'year': '1993', 'journal-title': 'Urol Clin North Am'}
/ Urol Clin North Am / Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia by Guess (1993)10.1159/000480851
/ Eur Urol / Indications for preoperative seminal vesicle biopsies in staging of clinically localized prostatic cancer by Guillonneau (1997)10.1016/S0022-5347(05)64668-X
/ J Urol / Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng/ml range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range by Haese (2002)10.1016/S0022-5347(17)34880-2
/ J Urol / Systematic sextant biopsies in 651 patients referred for prostate evaluation by Hammerer (1994)10.1016/S0094-0143(05)70163-4
/ Urol Clin North Am / Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy by Han (2001)10.1016/S0022-5347(17)38664-0
/ J Urol / Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate by Hodge (1989)10.1097/00005392-200202000-00018
/ J Urol / Cancer control with radical prostatectomy alone in 1000 consecutive patients by Hull (2002)10.1111/j.1464-410X.1985.tb07043.x
/ Br J Urol / Cord compression and carcinoma of the prostate: is laminectomy justified? by Iacovou (1985)10.1002/1097-0142(20010215)91:4<744::AID-CNCR1060>3.0.CO;2-C
/ Cancer / Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less by Ito (2001)10.1001/jama.1956.02960450020005
/ JAMA / Significance of the palpable prostatic nodule by Jewett (1956)10.1097/00042307-200303000-00005
/ Curr Opin Urol / Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer by Kattan (2003)10.1016/S0090-4295(01)01233-X
/ Urology / Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer by Kattan (2001)10.1200/JCO.1999.17.5.1499
/ J Clin Oncol / Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer by Kattan (1999)10.1200/JCO.2000.18.19.3352
/ J Clin Oncol / Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer by Kattan (2000)10.1016/0090-4295(94)90132-5
/ Urology / Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay by Katz (1994)10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B
/ Prostate / Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial by Labrie (1999)10.1016/S0022-5347(01)63951-X
/ J Urol / Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer by Levine (1998){'key': '10.1016/j.anuro.2004.06.003_BIB61', 'first-page': '63', 'article-title': 'Should we screen for prostate cancer?', 'volume': '32', 'author': 'Mangin', 'year': '1998', 'journal-title': 'Ann Urol'}
/ Ann Urol / Should we screen for prostate cancer? by Mangin (1998)10.1016/S0022-5347(05)64024-4
/ J Urol / Prostate biopsy: indications and technique by Matlaga (2003)10.3122/jabfm.16.2.95
/ J Am Board Fam Pract / Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma by Mistry (2003)10.1038/sj.pcan.4500472
/ Prostate Cancer Prostatic Dis / Targeted screening for prostate cancer in African-American men by Moul (2000)10.1016/S0094-0143(05)70155-5
/ Urol Clin North Am / The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy by Moul (2001)10.1001/jama.1993.03510070082041
/ JAMA / Serum prostate-specific antigen in a community-based population of healthy men by Oesterling (1993)10.1001/jama.1993.03500010067033
/ JAMA / The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer by Oesterling (1993)10.1016/S0022-5347(05)66318-5
/ J Urol / Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy by Park (2001)10.1016/S0022-5347(17)40079-6
/ J Urol / Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia by Partin (1990)10.1016/S0090-4295(01)01441-8
/ Urology / Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium by Partin (2001)10.1016/S0022-5347(17)35410-1
/ J Urol / The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer by Partin (1993)10.1002/(SICI)1097-0142(19990401)85:7<1586::AID-CNCR21>3.0.CO;2-F
/ Cancer / Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients by Polascik (1999)10.1016/S0022-5347(05)67995-5
/ J Urol / The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial by Presti (2000)10.1016/S0094-0143(02)00184-2
/ Urol Clin North Am / Imaging clinically localized prostate cancer by Purohit (2003)10.1016/S0090-4295(94)80095-2
/ Urology / Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy by Ravery (1994)10.1016/S0022-5347(01)61630-6
/ J Urol / The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study by Rietbergen (1999)10.1056/NEJM199009063231001
/ N Engl J Med / Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer by Rifkin (1990)10.1016/0360-3016(94)90138-4
/ Int J Radiat Oncol Biol Phys / Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer by Roach (1994)10.1016/S0022-5347(01)61941-4
/ J Urol / Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota by Roberts (1999){'issue': '6Pt1', 'key': '10.1016/j.anuro.2004.06.003_BIB80', 'first-page': '2115', 'article-title': 'Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature', 'volume': '160', 'author': 'Rodriguez', 'year': '1998', 'journal-title': 'J Urol'}
/ J Urol / Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature by Rodriguez (1998)10.1111/j.1464-410X.1992.tb15603.x
/ Br J Urol / Spinal cord compression in prostate cancer. A 10-year experience by Rosenthal (1992)10.1016/S0094-0143(02)00180-5
/ Urol Clin North Am / Screening for prostate cancer by Schroder (2003)10.1093/jnci/90.23.1817
/ J Natl Cancer Inst / Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer by Schroder (1998)10.1016/S0094-0143(21)00918-6
/ Urol Clin North Am / PSA density (PSAD). Role in patient evaluation and management by Seaman (1993)10.1016/S0090-4295(99)80452-X
/ Urology / Transperineal prostate needle biopsy guided by transurethral ultrasound in patients without a rectum by Seaman (1996)10.1016/S0090-4295(99)00193-4
/ Urology / Limitations of transperineal ultrasound-guided prostate biopsies by Shinghal (1999)10.1016/S0022-5347(01)62395-4
/ J Urol / Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men by Smith (1998)10.1016/S0022-5347(17)32528-4
/ J Urol / Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection by Smith (1994)10.1016/S0022-5347(01)65079-1
/ J Urol / Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial by Smith (1997)10.1016/S0022-5347(17)40216-3
/ J Urol / Positive surgical margins at radical prostatectomy: importance of the apical dissection by Stamey (1990)10.1056/NEJM198710083171501
/ N Engl J Med / Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate by Stamey (1987)10.1016/S0022-5347(05)66083-1
/ J Urol / Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies by Stewart (2001)10.1046/j.1464-410x.1999.00386.x
/ BJU Int / Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancers by Tombal (1999)10.1016/S0090-4295(98)00640-2
/ Urology / Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL by Tornblom (1999)10.1016/S0090-4295(02)02524-4
/ Urology / Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination by Uzzo (2003)10.1016/S0022-5347(05)64663-0
/ J Urol / Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives by Valeri (2002)10.1046/j.1464-410x.2001.02146.x
/ BJU Int / State-of-the-art staging in prostate cancer by Wilkinson (2001)10.1016/S0140-6736(00)03266-9
/ Lancet / Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening? by Wolk (2000)10.1148/radiology.213.2.r99nv26481
/ Radiology / Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging by Yu (1999)10.1046/j.1464-410x.1999.00214.x
/ BJU Int / The importance of measuring the prostatic transition zone: an anatomical and radiological study by Zlotta (1999)
Dates
Type | When |
---|---|
Created | 21 years ago (Aug. 27, 2004, 7:07 p.m.) |
Deposited | 4 years, 2 months ago (June 25, 2021, 3:29 a.m.) |
Indexed | 11 months, 2 weeks ago (Sept. 15, 2024, 12:26 p.m.) |
Issued | 20 years, 11 months ago (Oct. 1, 2004) |
Published | 20 years, 11 months ago (Oct. 1, 2004) |
Published Print | 20 years, 11 months ago (Oct. 1, 2004) |
@article{Fournier_2004, title={Cancer de la prostate. Diagnostic et bilan d’extension}, volume={38}, ISSN={0003-4401}, url={http://dx.doi.org/10.1016/j.anuro.2004.06.003}, DOI={10.1016/j.anuro.2004.06.003}, number={5}, journal={Annales d’Urologie}, publisher={Elsevier BV}, author={Fournier, G. and Valeri, A. and Mangin, P. and Cussenot, O.}, year={2004}, month=oct, pages={207–224} }